Vilket är priset för Arno Therapeutics, Inc. (ARNI)

Priset för Arno Therapeutics, Inc. (ARNI) är $0.0001

Vilket är marknadsvärdet för Arno Therapeutics, Inc. (ARNI)

Marknadsvärdet för Arno Therapeutics, Inc. (ARNI) är $4.94K

Arno Therapeutics, Inc. (ARNI) Pris och Marknadsvärde

Arno Therapeutics, Inc., headquartered in Flemington, New Jersey, operates as a biopharmaceutical enterprise focused on discovering and advancing treatments for cancer and other severe health conditions. The company's developmental portfolio includes several key compounds: Onapristone, a type 1 anti-progestin hormone blocker, is currently undergoing Phase I/II clinical trials. This therapeutic is being investigated for its efficacy in treating various solid tumors, such as breast and endometrial cancers in post-menopausal women, and advanced castration-resistant prostate cancer in men. AR-12, an orally administered cancer therapy, has successfully completed Phase I clinical studies for solid tumors and hematological malignancies. Additionally, it is in pre-clinical development for potential applications against a range of microbial targets. AR-42, another innovative oral cancer treatment, is involved in a Phase I investigator-initiated clinical study, targeting both hematological malignancies and solid tumors. To support its research and development efforts, Arno Therapeutics has established licensing agreements with Invivis Pharmaceuticals, Inc., the Regents of the University of Minnesota, and the Ohio State University Innovation Foundation. The company also holds a co-development partnership with Leica Biosystems Newcastle Ltd.

Pris för ARNI	Tillgång B	Marknadsvärdet för B	Resultat
$109,085 $4.94K	NVDA	$5.383T	+109,085,297,974.98%
$89,633.05 $4.94K	AAPL	$4.423T	+89,633,053,673.82%
$84,303.33 $4.94K	GOOG	$4.160T	+84,303,331,188.39%
$74,231.43 $4.94K	MSFT	$3.663T	+74,231,425,168.49%
$58,586.20 $4.94K	AMZN	$2.891T	+58,586,196,362.01%

Pris för ARNI

Tillgång B

Marknadsvärdet för B

Resultat

$109,085 $4.94K